Treatment of Overactive Bladder Symptoms Beyond Antimuscarinics: Current and Future Therapies
Treatment of Overactive Bladder Symptoms Beyond Antimuscarinics: Current and Future Therapies
复制标题
DOI：
10.3810/pgm.2012.05.2544
复制
发表时间：
2012-05-01
影响因子：
4.2
通讯作者：
Ellsworth, Pamela
中科院分区：
文献类型：
--
作者：
Ellsworth, Pamela
膀胱过度活动症（OAB）是一种常见的综合征，影响男性和女性。用于管理OAB症状的一线疗法包括抗毒蕈碱剂和行为疗法，理想情况下联合使用。虽然有效改善OAB症状，使用抗毒蕈碱治疗可能会受到副作用，禁忌症和反应不足的限制。目前的二线疗法包括骶神经刺激和经皮胫神经刺激。这些疗法已被证明可用于治疗OAB症状，但比药物治疗更具侵入性和耗时。Onabotelatin毒素A目前正在研究特发性OAB，以及β-3-肾上腺素受体激动剂米拉贝隆和索拉贝隆。这些药物的作用，具有不同的作用机制，在OAB的药理学管理仍有待确定，虽然他们似乎是有前途的替代品和可能的替代品，目前的药理学和行为治疗。本文讨论了二线和当前和未来的治疗OAB症状的管理。
Overactive bladder (OAB) is a common syndrome that affects both men and women. First-line therapies for the management of OAB symptoms consist of antimuscarinic agents and behavioral therapy, ideally used in combination. Although effective in improving OAB symptoms, the use of antimuscarinic therapy may be limited by side effects, contraindications, and insufficient response. Current second-line therapies include sacral nerve stimulation and percutaneous tibial nerve stimulation. These therapies have been shown to be useful in treating OAB symptoms, but are more invasive and time-consuming than medical therapy. Onabotulinum toxin A is currently under investigation for idiopathic OAB, as well as the beta-3-adreno-renoreceptor agonists mirabegron and solabegron. The role of these agents, with different mechanisms of action, in the pharmacologic management of OAB remains to be determined, although they appear to be promising alternatives and possible adjuncts to current pharmacologic and behavioral therapy. This article discusses second-line and current and future therapies for the management of OAB symptoms.